Literature DB >> 17198265

Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.

Masahiro Ohira1, Hideki Ohdan, Hiroshi Mitsuta, Kohei Ishiyama, Yuka Tanaka, Yuka Igarashi, Toshimasa Asahara.   

Abstract

BACKGROUND: Antitumor activity of the liver natural killer (NK) cells reportedly decreases after partial hepatectomy, suggesting that patients with such depressed immune status are susceptible to the recurrence of hepatocellular carcinoma (HCC). We hypothesize that adoptive immunotherapy using activated NK cells can be a novel strategy to improve the depressed immune status in patients with HCC after hepatectomy or partial liver transplantation. In the present study, we have tested this hypothesis by using a mouse model.
METHODS: Intraportal injection of 1-5 x 10(6) Hepa1-6 cells (hepatoma cell line) did not result in liver metastases in untreated B6 mice, but led to the growth of liver metastases after extensive partial hepatectomy. Utilizing this murine HCC metastasis model, we investigated the antitumor activity of both remnant liver and exogenously transferred NK cells.
RESULTS: The anti-HCC activity of liver NK cells significantly decreased after partial hepatectomy. The expression of CD69 and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on liver NK cells was temporarily downregulated. The adoptive transfer of NK cells, including a TRAIL-expressing fraction, extracted from the liver perfusates of poly I:C-stimulated B6 mice inhibited the growth of liver metastasis in B6 or (B6xBALB/c) F1 (B6CF1) mice that underwent hepatectomy and received intraportal Hepa1-6 injection.
CONCLUSIONS: These findings indicate that adoptive immunotherapy using activated NK cells extracted from normal liver perfusates may be a novel technique for reconstituting the depressed immune status in cases of living donor liver transplantation involving HCC patients, recipients of a partial liver graft.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17198265     DOI: 10.1097/01.tp.0000250935.41034.2d

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  26 in total

Review 1.  Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review.

Authors:  Jian-Hong Zhong; Qing-Lian Zhong; Le-Qun Li; Hang Li
Journal:  Tumour Biol       Date:  2014-08-14

Review 2.  Prevention of recurrence after curative treatment for hepatocellular carcinoma.

Authors:  Tsuyoshi Kobayashi; Kohei Ishiyama; Hideki Ohdan
Journal:  Surg Today       Date:  2012-12-28       Impact factor: 2.549

3.  Prevention of hepatitis C recurrence after liver transplantation: An update.

Authors:  Marco Carbone; Ilaria Lenci; Leonardo Baiocchi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06

4.  Liver Transplantation for HCC: A Review.

Authors:  Rahul Kakodkar; A S Soin
Journal:  Indian J Surg       Date:  2011-12-27       Impact factor: 0.656

5.  Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth.

Authors:  Uta Rabenhorst; Rasa Beinoraviciute-Kellner; Marie-Luise Brezniceanu; Stefan Joos; Frauke Devens; Peter Lichter; Ralf J Rieker; Jörg Trojan; Hye-Jung Chung; David L Levens; Martin Zörnig
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

Review 6.  Trial Watch: Adoptive cell transfer for oncological indications.

Authors:  Fernando Aranda; Aitziber Buqué; Norma Bloy; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-05-05       Impact factor: 8.110

7.  Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice.

Authors:  Masahiro Ohira; Kohei Ishiyama; Yuka Tanaka; Marlen Doskali; Yuka Igarashi; Hirotaka Tashiro; Nobuhiko Hiraga; Michio Imamura; Naoya Sakamoto; Toshimasa Asahara; Kazuaki Chayama; Hideki Ohdan
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

8.  Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression.

Authors:  Lei Yang; Jun-Ya Zhu; Jian-Guo Zhang; Bo-Jun Bao; Cheng-Qi Guan; Xiao-Jing Yang; Yan-Hua Liu; Yue-Jiao Huang; Run-Zhou Ni; Li-Li Ji
Journal:  Tumour Biol       Date:  2015-10-21

9.  Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.

Authors:  Masahiro Ohira; Ryuichi Hotta; Yuka Tanaka; Toshiharu Matsuura; Akin Tekin; Gennaro Selvaggi; Rodrigo Vianna; Camillo Ricordi; Phillip Ruiz; Seigo Nishida; Andreas G Tzakis; Hideki Ohdan
Journal:  Cancer Immunol Immunother       Date:  2021-07-19       Impact factor: 6.968

10.  Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.

Authors:  Lydia Kriegl; Andreas Jung; David Horst; Antonia Rizzani; Rene Jackstadt; Heiko Hermeking; Eike Gallmeier; Alexander L Gerbes; Thomas Kirchner; Burkhard Göke; Enrico N De Toni
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.